Aethlon Medical Advances Oncology Trial, Expands Hemopurifier IP Portfolio — Aethlon Medical, Inc.

Event summary

Aethlon Medical entered the third and final dosing cohort of its Australian oncology study, treating the first participant at Royal North Shore Hospital.
The company expanded its Hemopurifier intellectual property portfolio with new patents covering long COVID and coronavirus-related conditions, extending protection into the 2040s.
Operating expenses declined 21.9% year-over-year to $7.3 million, while cash reserves stood at $5.0 million as of March 31, 2026.
Aethlon raised $1.85 million in net proceeds through its at-the-market program subsequent to the fiscal year-end.

The big picture

Aethlon Medical's progress in its oncology trial and expansion of its Hemopurifier IP portfolio reflect its strategy to address unmet needs in oncology and infectious diseases. The company's focus on cost management and strategic fundraising positions it to navigate the challenges of clinical-stage development while pursuing opportunities in larger markets. The broader industry trend of targeting extracellular vesicles and viral pathogens underscores the potential scalability of Aethlon's platform technology.

What we're watching

Clinical Milestones: The pace at which Aethlon completes enrollment and generates data from all planned dosing regimens in the Australian oncology study will determine the next steps in Hemopurifier development.
Market Expansion: Whether Aethlon can successfully leverage its expanded IP portfolio to enter new disease areas, such as rheumatoid arthritis and chronic kidney disease, will be critical for long-term growth.
Financial Sustainability: How Aethlon balances its reduced operating expenses with the need for additional funding to support ongoing clinical and research activities will impact its ability to execute its strategic priorities.